Nguyên tắc thiết kế của một cấu trúc mới cho chỉnh sửa gen HBB và điều tra hiệu quả nhắm mục tiêu gen của nó trong tế bào HEK293

Jaing, T.-H., Chang, T.-Y., Chen, S.-H., Lin, C.-W., Wen, Y.-C., & Chiu, C.-C. (2021). Molecular genetics of β-thalassemia: A narrative review. Medicine, 100(45), e27522. Rattananon, P., Anurathapan, U., Bhukhai, K., & Hongeng, S. (2021). The future of gene therapy for transfusion-dependent beta-thalassemia: The power of the lentiviral vector for genetically modified hematopoietic stem cells. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.730873 Cosenza, L. C., Gasparello, J., Romanini, N., Zurlo, M., Zuccato, C., Gambari, R., & Finotti, A. (2021). Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients. Molecular Therapy-Methods & Clinical Development, 21, 507–523. Hossain, M. S., Raheem, E., Sultana, T. A., Ferdous, S., Nahar, N., Islam, S., Arifuzzaman, M., Razzaque, M. A., Alam, R., & Aziz, S. (2017). Thalassemias in South Asia: Clinical lessons learnt from Bangladesh. Orphanet Journal of Rare Diseases, 12(1), 1–9. Rezabeigi Davarani, E., Mohseni Takaloo, F., Vahidnia, A., Daneshi, S., Rezabeigi Davarani, M., Khanjani, N., Hushmandi, K., & Raei, M. (2020). Epidemiological investigation of a twenty-year major β-thalassemia surveillance in Kerman, Iran. Archives of Hygiene Sciences, 9(4), 265–274. Guha, T. K., Wai, A., & Hausner, G. (2017). Programmable genome editing tools and their regulation for efficient genome engineering. Computational and Structural Biotechnology Journal, 15, 146–160. Carroll, D. (2014). Genome engineering with targetable nucleases. Annual Review of Biochemistry, 83, 409–439. Tafazoli, A., Behjati, F., Farhud, D. D., & Abbaszadegan, M. R. (2019). Combination of genetics and nanotechnology for down syndrome modification: A potential hypothesis and review of the literature. Iranian Journal of Public Health, 48(3), 371. Gaj, T., Gersbach, C. A., & Barbas, C. F., III. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, 31(7), 397–405. Sander, J. D., & Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology, 32(4), 347–355. Bazi, A., & Miri-Moghaddam, E. (2016). Spectrum of β-thalassemia mutations in Iran, an update. Iranian Journal of Pediatric Hematology & Oncology, 6(3), 190–202. Saha, D., Patgaonkar, M., Shroff, A., Ayyar, K., Bashir, T., & Reddy, K. (2014). Hemoglobin expression in nonerythroid cells: Novel or ubiquitous? International Journal of Inflammation, 2014, 1–8. Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., & Mantri, S. (2016). CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 539(7629), 384–389. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., & Handgretinger, R. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. Firth, A. L., Menon, T., Parker, G. S., Qualls, S. J., Lewis, B. M., Ke, E., Dargitz, C. T., Wright, R., Khanna, A., & Gage, F. H. (2015). Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs. Cell Reports, 12(9), 1385–1390. Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., & van der Ent, C. K. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13(6), 653–658. Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., & Sakurai, H. (2015). Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 4(1), 143–154. Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications, 6(1), 1–13. Monteys, A. M., Ebanks, S. A., Keiser, M. S., & Davidson, B. L. (2017). CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Molecular Therapy, 25(1), 12–23. Shin, J. W., Kim, K.-H., Chao, M. J., Atwal, R. S., Gillis, T., MacDonald, M. E., Gusella, J. F., & Lee, J.-M. (2016). Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9. Human Molecular Genetics, 25(20), 4566–4576. De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., & Garofalo, M. (2017). CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Science Translational Medicine, 9(372), eaah3480. Flynn, R., Grundmann, A., Renz, P., Hänseler, W., James, W. S., Cowley, S. A., & Moore, M. D. (2015). CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Experimental Hematology, 43(10), 838–848. Guan, Y., Ma, Y., Li, Q., Sun, Z., Ma, L., Wu, L., Wang, L., Zeng, L., Shao, Y., & Chen, Y. (2016). CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Molecular Medicine, 8(5), 477–488. Park, C.-Y., Kim, D. H., Son, J. S., Sung, J. J., Lee, J., Bae, S., Kim, J.-H., Kim, D.-W., & Kim, J.-S. (2015). Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell, 17(2), 213–220. Chung, J. E., Magis, W., Vu, J., Heo, S.-J., Wartiovaara, K., Walters, M. C., Kurita, R., Nakamura, Y., Boffelli, D., & Martin, D. I. (2019). CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells. PLoS ONE, 14(1), e0208237. Khosravi, M. A., Abbasalipour, M., Concordet, J.-P., Vom Berg, J., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019). Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European Journal of Pharmacology, 854, 398–405. Martyn, G. E., Wienert, B., Yang, L., Shah, M., Norton, L. J., Burdach, J., Kurita, R., Nakamura, Y., Pearson, R., & Funnell, A. P. (2018). Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nature Genetics, 50(4), 498–503. Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., & Luk, K. (2019). Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 3(21), 3379–3392. Niu, X., He, W., Song, B., Ou, Z., Fan, D., Chen, Y., Fan, Y., & Sun, X. (2016). Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in β-thalassemia-induced pluripotent stem cells. Journal of Biological Chemistry, 291(32), 16576–16585. Patsali, P., Mussolino, C., Ladas, P., Floga, A., Kolnagou, A., Christou, S., Sitarou, M., Antoniou, M. N., Cathomen, T., & Lederer, C. W. (2019). The scope for thalassemia gene therapy by disruption of aberrant regulatory elements. Journal of Clinical Medicine, 8(11), 1959. Patsali, P., Turchiano, G., Papasavva, P., Romito, M., Loucari, C. C., Stephanou, C., Christou, S., Sitarou, M., Mussolino, C., & Cornu, T. I. (2019). Correction of IVS I–110 (G> A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells. Haematologica, 104(11), e497. Shariati, L., Rohani, F., Heidari Hafshejani, N., Kouhpayeh, S., Boshtam, M., Mirian, M., Rahimmanesh, I., Hejazi, Z., Modarres, M., & Pieper, I. L. (2018). Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β-thalassemia. Journal of Cellular Biochemistry, 119(11), 9357–9363. Weber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., & Chalumeau, A. (2020). Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Science Advances, 6(7), eaay9392. Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., & Baricordi, C. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine, 25(5), 776–783. Xiong, Z., Xie, Y., Yang, Y., Xue, Y., Wang, D., Lin, S., Chen, D., Lu, D., He, L., & Song, B. (2019). Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides. Journal of Cellular and Molecular Medicine, 23(12), 8046–8057. Xu, P., Tong, Y., Liu, X.-Z., Wang, T.-T., Cheng, L., Wang, B.-Y., Lv, X., Huang, Y., & Liu, D.-P. (2015). Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs. Scientific Reports, 5(1), 1–12. Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020). Gene editing and CRISPR in the clinic: current and future perspectives. Bioscience Reports. https://doi.org/10.1042/BSR20200127 Ming, S., Tian-Rui, X., & Ce-Shi, C. (2016). The big bang of genome editing technology: Development and application of the CRISPR/Cas9 system in disease animal models. Zoological Research, 37(4), 191. Ceasar, S. A., Rajan, V., Prykhozhij, S. V., Berman, J. N., & Ignacimuthu, S. (2016). Insert, remove or replace: A highly advanced genome editing system using CRISPR/Cas9. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1863(9), 2333–2344. El-Kenawy, A., Benarba, B., Neves, A. F., de Araujo, T. G., Tan, B. L., & Gouri, A. (2019). Gene surgery: Potential applications for human diseases. EXCLI Journal, 18, 908. Papasavva, P., Kleanthous, M., & Lederer, C. W. (2019). Rare opportunities: CRISPR/Cas-based therapy development for rare genetic diseases. Molecular Diagnosis & Therapy, 23(2), 201–222. Antony, J. S., Latifi, N., Haque, A., Lamsfus-Calle, A., Daniel-Moreno, A., Graeter, S., Baskaran, P., Weinmann, P., Mezger, M., & Handgretinger, R. (2018). Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. Molecular and Cellular Pediatrics, 5(1), 1–7. Cai, L., Bai, H., Mahairaki, V., Gao, Y., He, C., Wen, Y., Jin, Y.-C., Wang, Y., Pan, R. L., & Qasba, A. (2018). A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease. Stem Cells Translational Medicine, 7(1), 87–97. Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., & Li, Y. (2015). CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell, 6(5), 363–372. Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014). Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research, 24(9), 1526–1533. Yang, H., Ren, S., Yu, S., Pan, H., Li, T., Ge, S., Zhang, J., & Xia, N. (2020). Methods favoring homology-directed repair choice in response to CRISPR/Cas9 induced-double strand breaks. International Journal of Molecular Sciences, 21(18), 6461. Song, F., & Stieger, K. (2017). Optimizing the DNA donor template for homology-directed repair of double-strand breaks. Molecular Therapy-Nucleic Acids, 7, 53–60. Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 153(4), 910–918. Dickinson, D. J., Ward, J. D., Reiner, D. J., & Goldstein, B. (2013). Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nature Methods, 10(10), 1028–1034. Azhagiri, M. K. K., Babu, P., Venkatesan, V., & Thangavel, S. (2021). Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy. Stem Cell Research & Therapy, 12(1), 1–12. Kim, H., Kim, M.-S., Wee, G., Lee, C.-I., Kim, H., & Kim, J.-S. (2013). Magnetic separation and antibiotics selection enable enrichment of cells with ZFN/TALEN-induced mutations. PLoS ONE, 8(2), e56476. Mitzelfelt, K. A., McDermott-Roe, C., Grzybowski, M. N., Marquez, M., Kuo, C.-T., Riedel, M., Lai, S., Choi, M. J., Kolander, K. D., & Helbling, D. (2017). Efficient precision genome editing in iPSCs via genetic co-targeting with selection. Stem Cell Reports, 8(3), 491–499. Quintana-Bustamante, O., Fañanas-Baquero, S., Orman, I., Torres, R., Duchateau, P., Poirot, L., Gouble, A., Bueren, J. A., & Segovia, J. C. (2019). Gene editing of PKLR gene in human hematopoietic progenitors through 5′ and 3′ UTR modified TALEN mRNA. PLoS ONE, 14(10), e0223775. Supharattanasitthi, W., Carlsson, E., Sharif, U., & Paraoan, L. (2019). CRISPR/Cas9-mediated one step bi-allelic change of genomic DNA in iPSCs and human RPE cells in vitro with dual antibiotic selection. Scientific Reports, 9(1), 1–7. Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M., Aiuti, A., & Deola, S. (2003). Safety of retroviral gene marking with a truncated NGF receptor. Nature Medicine, 9(4), 367–369. Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., & Peccatori, J. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study. The Lancet Oncology, 10(5), 489–500. Oliveira, G., Ruggiero, E., Stanghellini, M. T. L., Cieri, N., D’Agostino, M., Fronza, R., Lulay, C., Dionisio, F., Mastaglio, S., & Greco, R. (2015). Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Science Translational Medicine, 7(317), 317ra198-317ra198. Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science, 351(6268), 84–88. Osborn, M. J., Belanto, J. J., Tolar, J., & Voytas, D. F. (2016). Gene editing and its application for hematological diseases. International Journal of Hematology, 104(1), 18–28.